Table 1.

COVID-19 vaccines approved for use around the world

Vaccine	Manufacturer	Type	Details	Dosage	Safety data from clinical trials: serious adverse events
BNT162b2	Pfizer, Inc. and BioNTech (COMIRNATY)	mRNA	Lipid nanoparticle formulated nucleoside- modified mRNA vaccine encoding prefusion stabilized, membrane-anchored full length SARS-CoV-2 spike (S) glycoprotein	12 years or older 2 doses 21 days apart Additional dose- recommended for moderate to severely immunocompromised people- 4 weeks after the 2nd dose Booster- Some groups of people are recommended to get a booster shot at least 6 months after getting their second shot	Myocarditis or pericarditis: rare, 12.6/100000 adolescents and young adults
mRNA-1273	ModernaTX, Inc	mRNA	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2	18 years or older 2 doses, 28 days apart Additional dose- recommended for moderate to severely immunocompromised people- 4 weeks after the 2nd dose	Myocarditis or pericarditis: rare, 12.6/100000 adolescents and young adults
ChAdOx1 nCoV-19 Corona Virus Vaccine AZD1222	Serum Institute of India- Covishield AstraZeneca- Vaxzevria	Viral vector- based	Recombinant vaccine from the genetically modified human embryonic kidney (HEK) 293 cells with replication- deficient chimpanzee adenovirus vector encoding SARS-CoV-2 Spike (S) glycoprotein. Induces binding and neutralizing antibodies and interferon-gamma enzyme-linked immunospot responses.	2 doses 12-16 weeks apart	Cerebral venous sinus thrombosis, thrombosis with thrombocytopenia
JNJ-78436735 Ad26COV2.S	Janssen Pharmaceuticals Companies of Johnson and Johnson	Viral vector-based	Recombinant, replication-incompetent Ad26 vector, encoding a stabilized variant of the SARS-CoV-2 DNA encoding Spike (S) protein	18 years or older 1 shot Additional doses- not recommended Booster- At least 2 months after receiving your vaccine. You can get any of the COVID-19 vaccines authorized in the United States for your booster shot	Thrombosis with thrombocytopenia syndrome: 7/100000 vaccinated women 18-49 years Guillain-Barré syndrome
Gam- COVID-Vac	Sputnik V Gamaleya National Research Centre	Viral vector-based	Heterologous recombinant adenovirus approach with adenovirus (Ad26) and adenovirus 5 (Ad5) as vectors for expression of SARS-CoV-2 spike protein	18 years or older Two doses, 21 days apart
BBV152	COVAXIN Bharat Biotech	Inactivated coronavirus Vaccine	The whole virion inactivated Imidazoquinoline class molecule (TLR 7/8 agonist) adsorbed to alum	18 years or older 2 doses, 28 days apart
BBIBP-CorV	Sinopharm	Inactivated coronavirus vaccine	An inactivated vaccine with aluminum-based adjuvant	2 doses 3-4 weeks apart	Inflammatory demyelination syndrome, acute disseminated encephalomyelitis
CoronaVac	Sinovac Biotech Ltd Beijing	Inactivated coronavirus vaccine	The whole virion inactivated vaccine. Aluminum hydroxide adjuvant	18 years or older 2 doses, 2-4 weeks apart Additional dose- recommended for moderate to severely immunocompromised people - 4 weeks after the 2nd dose	Booster - not recommended yet